1. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : final evidence report Publication: Boston, MA : Institute for Clinical and Economic Review, December 2 2016 Subject(s): Comparative Effectiveness ResearchImmunologic Factors -- therapeutic usePsoriasis -- drug therapyAdalimumab -- therapeutic useBenchmarkingEtanercept -- therapeutic useImmunologic Factors -- adverse effectsImmunologic Factors -- economicsInterleukin-12 -- antagonists & inhibitorsInterleukin-17Interleukin-23 -- antagonists & inhibitorsPhosphodiesterase 4 InhibitorsPhototherapyPsoriasis -- immunologyPsoriasis -- therapyRandomized Controlled Trials as TopicSeverity of Illness IndexTumor Necrosis Factor-alpha -- antagonists & inhibitorsUstekinumab -- therapeutic useValue-Based PurchasingHumansUnited States
2. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value : condition update : final evidence report Publication: [Boston, Massachusetts] : Institute for Clinical and Economic Review, August 3, 2018 Subject(s): Immunologic Factors -- therapeutic useImmunomodulationPsoriasis -- drug therapyCertolizumab Pegol -- therapeutic useClinical Trials as TopicCost-Benefit AnalysisImmunologic Factors -- adverse effectsImmunologic Factors -- economicsQuality of LifeTreatment OutcomeHumansUnited States
